ATOS trade ideas
$ATOS PT 4-4.50Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. Atossa Therapeutics, Inc. has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the potential treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Added $ATOS Target 4.11 for 29.25% $ATOS Target 4.11 for 29.25%
Or next add level is at - well anywhere under the red line is a good place to add...
—
On the far right of the chart is my Average (Grey) Current Target (Green), and Next Level to add (Red) Percentage to target is from my average.
I start every position with 1% of my account and build from there as needed and as possible.
I am not your financial advisor. Watch my setups first before you jump in… My trade set ups work very well and they are for my personal reference and if you decide to trade them you do so at your own risk. I will gladly answer questions to the best of my knowledge but ultimately the risk is on you. I will update targets as needed.
GL and happy trading.
Long | ATOS | This is a rare opportunityNASDAQ:ATOS
1- It's at support level right now, consolidated for 2 weeks.
2- It had a direct offering of 50m$ 2 weeks ago, new Institutional investors joined the team, they already had public offering and they didn't need any cash, they have cash for 3-4 years of operational cost.
3- it has 2 products for waiting P2 approval, one if them halted in Feb, because the results were great but didn't published the official approval from FDA yet, (Expected in 2 weeks)
4- it has a cure for cancer, put money in this company is a good cause and RIO is insane,
5- Average of price target is 6.25$, it means 300% .
6- buy-out is one of the possible options, and I expect an average price of 11$, it should be happen before shareholder meeting (less than 2 month)
* these are my ideas and could be wrong 100%, but if it be right thanks me later. lol
ATOS - Triple Bottom with a Breakout?Set up looks great. Triple bottom, break out and retest of a diagonal resistance. I absolutely dislike stocks like this but I like the chart. Will there be a catalyst to move this? The only catalyst for this one is the recent FDA "safe to proceed" letter to continue ovarian cancer treatment. If it actually materializes, could see a run towards levels above. It will only move if it catches momo crowd, otherwise just another garbage stonk.
SHORT | ATOSNASDAQ:ATOS
As you see in chart, it's in downtrend,
key levels are 2.90 as break-out
2.65 as break-down
ATOS ?NASDAQ:ATOS
It looks bearish to me,
The patterns I see are:
1- Symmetric Pennant
2- Downtrend for last 2 days in 15min
3- Downtrend for last 6 days in 1h
ATOS ?
NASDAQ:ATOS
* 2.65 is line between bullish and bearish, if it drops TP1: 2.35 if it goes up: TP ~3.05, 2.90 Pivot point, they all aligned to Fibo levels.
* Price moved below Ichimoku cloud
* Elder bar turned red
Short share availability:
2021-03-15 17:17:10.871 6,900,000
2021-03-16 22:02:07.828 5,800,000
1.1m short position opened today,
Long | ATOSNASDAQ:ATOS
Updated chart pattern on ATOS: the bullish pennant changed to Symmetric Triangle, By nature of this pattern, it has potential to go up or down, but when we study other variables and recent price actions I expect a break-out not break-down, price target for symmetric triangle is equal to the distance from the high and low of the earliest part of the pattern applied to the breakout price point. For example, for ATOS low of $2.45 and move up to $3.80 before the price range narrows over time. A breakout from $2.45 would imply a price target of ~$4.30, or $3.80 – $2.45 = $1.35, then + $3 = $4.35. it's exactly fit to the Fibonacci level 1, $4.33. I put mental SL around 2.80, to reduce my shares and buy cheaper, if to goes down, it goes to 2$
Long | ATOSNASDAQ:ATOS
Possible Scenario: LONG
Evidence: Price Action
This is my idea and could be wrong 100%,
$ATOSI’m going to continue accumulating ATOS for several months, probably half a year.
The momentum is back and the future looks bright now.
We have SUPPORT at $1.90 and RESISTANCE at $3.90
Once we get past $3.90 it should take off, BUT, I wouldn’t buy there, I would buy closer to the low (support @ 1.90 - 2.00).
“ Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington. “
$ATOS Target 4.29 for 27.68% $ATOS Target 4.29 for 27.68%
Please only trade my set ups at your own risk. I am not your financial advisor.
ATOS Trend ReversalFalling wedge on ATOS indicative of trend reversal. Expecting a test around $3.35 and will buy if it bounces. Expecting a high growth after uptrend begins as the stock has been moving in big leaps.
Short trade candidate: $ATOSFIBO and extended FIBO followed, Stochastic RSI shows it is oversold and very bullish green SOR is present. This is a good catch tomorrow.
ATOS to the MoonAtossa Therapeutics has potentially come out with a new and innovative treatment for cancer. It isn't a sure thing, but once the public hears more about the drug and they start to get into late-stage clinical trials, this stock could skyrocket. Good Luck!
SMALLCAP - FUNDAMENTAL & TECHNICAL - ATOS Long to 15Price Action:
- Contrarian investing and whale hunting lead me to this stock... when I see high effort to short, I see opportunity. Usually when institutions find a stock they want, they will attack with naked shorting and FUD to drive the price down and shake out retail.
- 4% inst. owned, +330% inst. transactions, confirming my suspicions.
- 70M Float, this one will be hard to keep down.
- Take a look at the huge accumulating since March. Somebody knows something is up.
Fundamentals:
"The AT-301 formulation was designed to work like a mucosal vaccine, blocking entry of the virus into the cells to begin with and thus, hopefully, preventing a COVID-19 infection"
"AT-301 is being developed with a nasal spray delivery mechanism because many COVID-19 patients are infected via the nasal passage. Collectively, the components of AT-301 are believed to help maintain a protective mucosal like layer within the nasal cavity with both anti-viral properties and protective mucosal like barrier that may lead to lower infectivity and reduced symptoms in COVID-19 patients due to their interference with the spike protein of the virus in the nasal cavity and upper respiratory tract. Atossa’s nasal spray formulation AT-301 is being designed to contain ingredients that can potentially block SARS-CoV-2 viral entry gene proteins in nasal epithelial cells by interfering with spike protein activation by host proteases, by masking receptor binding domains (RBD) via electrostatic mechanisms, and by providing a generalized mucoadhesive epithelial barrier."
"The study is a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects divided into two study groups. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A. Part B is a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days."
- Potential breakthroughs in cancer and COVID research... Pharma is taking off, this company WILL be pumped
Could be the next big one.. I won't be sleeping on this opportunity.
ATOS area of valueOne of my favorite trade setups and success rate is fairly high...
This is a great point of entry, price is above 200MA and MACD signal line below 0 ready to fire! Wait for the cross and load up. A buy signal from TRND will be my confirmation here! Low risk at this area of value setting my stops below support. Load up on the calls!
Trade smart with clean charts! Like follow and share! Thank you!
ATOS - READY FOR A THIRD AND FINAL RUNExtremely oversold, perfect consolidation for a final run to test the 4.97 resistance. Volume is bottoming off again as well, further confirming that this is the lowest we'll see it.
